Desk›Healthcare› Rekvina Laboratories Ltd
Rekvina Laboratories Ltd
BSE 526075 · NSE VINRKLB · ISIN INE092O01028 · Group XT · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹47.83
+1.98%
BSE close, 28 August 2026
₹28.83 cr
0.6 cr shares · Micro cap
₹16.92 cr
as published
-83.9× · -683.29×
EPS ₹-0.57 · BV ₹-0.07
1.27 / -0.26
₹ cr, as filed
17
4 selected · 24%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | +0.0% |
|---|---|
| Against 52-week low | +608.6% |
| Day change | +1.98% |
| Size band | Micro cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹-0.57 |
|---|---|
| Price / earnings | -83.91× |
| Price / book | -683.29× |
| Book value — derived, price ÷ P/B | ₹-0.07 |
| Return on equity | 466.48% |
| Operating margin | -18.09% |
| Net margin | -18.09% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 814.31%
- ROE as published
- 466.48%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 0.67 | -0.12 | -0.20 | -18.09% | -18.09% |
| Mar-26 · Q | 0.72 | -0.06 | -0.10 | -8.43% | -8.43% |
| FY25-26 | 1.27 | -0.26 | -0.42 | -20.16% | -20.16% |
Quarter on quarter
- Revenue, quarter on quarter
- -6.9%
- Net profit, quarter on quarter
- -100.0%
- Operating margin, quarter on quarter
- -966 bps
Disclosure profile 17 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Board Outcome | 1 |
| Change in Management | 1 |
| KMP | 1 |
| Results | 1 |
| Selected sub-total | 4 |
| Procedural | |
| AGM / EGM | 3 |
| General | 3 |
| SAST | 2 |
| Allotment | 1 |
| Annual Report | 1 |
| Clarification | 1 |
| Registered Office | 1 |
| Trading Window | 1 |
| Procedural sub-total | 13 |
| Total | 17 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group XT, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
17 filings · 4 selected · busiest 2026-08-12 and 2026-08-13
Filing rhythm · the twelve most recent
2026-08-142026-10-07
SelectedProcedural
Filings
17 in the window · 9 earlier on record
-
7 October 2026 ·
Change in Management
Appointment of Mr. Subrata Samanta as a Chief Financial officer of the company with effect from 07.10.2026.
Company Update / Change in Management View filing →
-
29 September 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
AGM Voting Results along-with Scrutinizer Report on E-Voting
AGM/EGM / AGM View filing →
-
29 September 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Summary of Proceeding of Annual General Meeting
AGM/EGM / AGM View filing →
-
24 September 2026 ·
Closure of Trading Window
Closure of Trading Window
Insider Trading / SAST / Closure of Trading Window View filing →
-
23 September 2026 ·
Announcement Under Reg. 30 Of SEBI (LODR) Regulation 2015 - Noting Of Resignation
Announcement under Reg. 30 of SEBI (LODR) Regulation 2015- Noting of Resignation
Company Update / General View filing →
-
23 September 2026 ·
Change in Registered Office Address
Change in Registered Office w.e.f. 23.09.2026
Company Update / Change in Registered Office Address View filing →
-
3 September 2026 ·
-
3 September 2026 ·
Shareholder's Meeting To Be Held On 29.09.2026 Through Online Mode
Shareholder's Meeting to be held on 29.09.2026 through online mode
AGM/EGM / AGM View filing →
-
2 September 2026 ·
Resignation of Company Secretary / Compliance Officer
Resignation of Mr. Deepak Khandelwal from the position of Company Secretary and Compliance Officer
Company Update / Resignation of Company Secretary / Compliance Officer View filing →
-
18 August 2026 ·
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Surbhit Mukesh Shah & Others
Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →
-
17 August 2026 ·
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dhruvalkumar Patel
Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 View filing →
-
14 August 2026 ·
Clarification On Price Movement
Clarification on Price Movement
Company Update / General View filing →
-
13 August 2026 ·
-
13 August 2026 ·
Board Meeting Outcome for OUTCOME OF BOARD MEETING
OUTCOME OF BOARD MEETING
Board Meeting / Outcome of Board Meeting View filing →
-
12 August 2026 ·
Clarification sought from Rekvina Laboratories Ltd
The Exchange has sought clarification from Rekvina Laboratories Ltd on August 12, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Company Update / Clarification
-
12 August 2026 ·
Allotment
Allotment of Equity Shares on Preferential basis
Company Update / Allotment of Equity Shares View filing →
-
31 July 2026 ·
Post Offer Advertisement
Vivro Financial Services Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Post Offer Advertisement in accordance with Regulation 18(12) of the Securities Exchange Board ....
Company Update / General View filing →
RSS feed for Rekvina Laboratories Ltd · the 50 most recent filings